News > calendarindustry

ABSTRACT

Background: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablative radiotherapy (SABR) is of utmost importance to prevent or delay start of ADT and its side effects.

Because Prostate-Specific Membrane Antigen-11- Positron Emission Tomography (PSMA-11-PET) has a higher sensitivity than choline-PET, we hypothesise that PSMA-11-PET based SABR results in longer response duration and subsequent longer delay in starting ADT than choline-PET.

METHODS

Patients with oligometastatic (≤4 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR.
Results: Fifty patients (n = 40 PSMA-11-PET and n = 10 choline-PET) with in total 72 lesions were included. Median follow-up was 24.3 months. PSMA-11-PET enabled eligibility of patients with lower PSA levels than choline-PET (median 1.8 versus 4.2 ng/mL, p = 0.03). The PSMA-11-PET group had a significant longer PSA response duration (median 34.0 months (95% confidence interval (CI), 16.0–52.0) versus 14.7 months (95% CI 4.7–24.7), p = 0.004) with a subsequent longer ADT-free survival (median 32.7 months (95% CI, 20.8–44.5) versus 14.9 months (95% CI, 5.7–24.1), p = 0.01).

CONCLUSION

With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.

Read the full article

The Canadian Association of Nuclear Medicine (CANM) Executive Director, Hélène Samson, retired on March 1, 2021. The CANM will be under the management of NAD Marketing Inc. with Nicolas Rondeau Lapierre the General Manager. Effective immediately the CANM will have a new office location and address, however the email and website addresses remain the same.
186, Val-Chenaie
Rosemère Québec, Canada J7A 4B6
(+1) 514-963-3269
Email:  canm@canm-acmn.ca
Website:  www.canm-acmn.ca

New study to explore ways to strengthen delivery of life-saving medical isotopes

TORONTO – June 3, 2020) – The Nuclear Innovation Institute (NII) and Canadian Nuclear Isotope Council (CNIC) have partnered in an innovative study to identify challenges and evaluate potential technology, logistical, regulatory and policy solutions in Canada’s medical isotope supply chain.

Canada is a Leader in the production and Global supply of Isotopes. During the COVID-19 Pandemic, this has been never been more evident supplying critical Isotopes for medical equipment sterilization and the diagnosis and treatment of cancer.

Abstract :

Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.

BARCELONA, Spain, 13th October 2019 – McMaster University’s Nuclear Reactor (CAN) and NRG (NL) announced today a unique collaboration between the Netherlands and Canada in the field of nuclear medicine.

Working together, these two globally renowned research reactors will provide the world with the highest quality radioiodine (I-125), used for the treatment of prostate and other various types of cancers, at the highest level of reliability.

The importance of readily available medical isotopes

Read the full article

Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a down-stream effect of AR activity is a promising rationale for management of this disease. (more…)

5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.
(more…)

The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and 177Lu-DOTATATE in malignant PGL patients. (more…)

Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. (more…)

Bone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. (more…)

The worldwide supply of molybdenum-99 is expected to stabilize over the next several weeks as the High Flux Reactor in the Netherlands and the Open Pool Australian Lightwater nuclear reactor have resumed operations and are expected to reach normal Mo-99 production this week. Meanwhile, NTP Radioisotopes’ South Africa-based Pelindaba Nuclear Plant, which has finished functionality tests, is awaiting approval from the country’s National Nuclear Regulator to begin Mo-99 production runs.

Read the full article.

Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. (more…)

A generous donor has given the B.C. Cancer Foundation $18.346 million, but insists on remaining anonymous.

“Today marks an important moment in cancer research and care in Canada with one of the largest donations ever made to bring new treatment solutions to patients,” said¬†Sarah Roth, president and¬†CEO of the¬†B.C.¬†Cancer Foundation. (more…)

INTRODUCTION: Prostate-specific membrane antigen (PSMA) is an excellent prostate cancer target for theranostic applications. Many imaging agents showing high sensitivity/specificity for PSMA-expressing tissues have been developed. Some have been labeled with therapeutic radionuclides (i.e. 177Lu, 225Ac) and have had success in treating castration-resistant metastatic prostate cancer. The activity administered to patients is limited by toxicity to normal organs;

(more…)

This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted. (more…)

Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)

Since China was the highlighted country of 2018 SNMMI in Philadelphia, several CSNM board members presented a brief report of 2018 SNMMI to the audience. One interesting fact needs attention is that Lu-177 is the most discussed topic this year not only because Lu-177 is highly in demand during SNMMI, but also more and more professors and doctors in China have realized how important and effective Lu-177 is when it is used to diagnose and treat prostate cancer. (more…)

Y-90 radioembolization for HCC patients with PVT appears to have an acceptable safety profile, with better survival in CP-A patients than in CP-B patients. This study confirms prior reports of survival in PVT patients treated with Y-90 radioembolization, and survival after Y-90 radioembolization appears to exceed that in
similar patients treated with systemic therapies. Despite the negative studies recently reported, Y-90 radioembolization is a reasonable treatment option in properly selected PVT patients. Further controlled studies are needed to compare it with systemic therapies or other locoregional treatments for advanced-stage HCC.

Nadine Abouchaleh1, Ahmed Gabr1, Rehan Ali1, Ali Al Asadi1, Ronald A. Mora1, Joseph Ralph Kallini1, Samdeep Mouli1, Ahsun Riaz1, Robert J Lewandowski1, and Riad Salem1–3

Info on purchasing Y-90, please contact sales@isosolutions.com

Read the full article PDF

isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine (http://www.csnm.com.cn/) in Sichuan, China.

The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. (more…)

PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) ‚Äì In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). (more…)

By Wayne Forrest, AuntMinnie.com staff writer.

Major changes are taking place in the intricate network that supplies healthcare providers around the world with molybdenum-99 (Mo-99), a key radioisotope for nuclear medicine studies. The question is, can the nuclear medicine community avoid another devastating shutdown like the one that occurred in 2009? (more…)

A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.

Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2

Info on purchasing Ac-225, please contact sales@isosolutions.com .

Read the full article PDF

The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students. This scholarship is granted to a student at Langara College in Vancouver.  To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in Marketing.

(more…)

PET/CT-guided percutaneous biopsy can be safely and accurately performed within the PET/CT suite without reinjection of the¬†89Zr-labeled radiotracer after the initial injection for diagnostic imaging.¬†89Zr-labeled radiotracers targeting specific proteins may be useful for both detection and molecular profiling in high-risk patients presenting with widely disseminated disease. Studies such as this may add clinical justification for the use of molecular imaging in interventional oncology and for promoting future access to interventional PET imaging facilities. (more…)

Key findings of the study:

• Using PET scans instead of SPECT scans resulted in increased rates of diagnosis of severe obstructive coronary artery disease from 70 percent to 79 percent.
• PET scans were associated with a lower incidence of invasive catheterization without identification of severe coronary artery disease (43% vs 55%). (more…)

^99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using ^99mTc -sestamibi for patients with coronary artery disease.

The WATERDAY study: Denis Agostini & Vincent (more…)

During the last decade, the utilization of ⁶⁸Ga for the development of imaging agents has increased considerably with the leading position in the oncology. The imaging of infection and inflammation is lagging despite strong unmet medical needs. This review presents the potential routes for the development of ⁶⁸Ga-based agents for the imaging and quantification of infection and inflammation in various diseases and connection of the diagnosis to the treatment for the individualized patient management. (more…)

Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target.¬†This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting Œ±vŒ≤3 integrin, occurs in¬†prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)

The first Peptide Receptor Radionuclide Therapy (PRRT) has received FDA approval. Lutetium 177 DOTA-TATE (Lu 177), a type of PRRT, is now approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors in adults.

FDA approval of PRRT using Lu-177 will allow more eligible U.S. patients to receive this “life extending” treatment. Lu-177 is manufactured by Advanced Accelerator Applications (AAA), a Novartis company. Prior to the FDA approval, PRRT with Lu-177 was only available in a limited number of American treatment centers as part of an expanded access program or through a clinical trial.

Click here to see full news release.

Transcatheter hepatic artery embolization therapy is a minimally invasive alternative for treating inoperable liver cancer, but recurrence is frequent. Multifunctional agents could offer an opportunity for tumor eradication. In this article, the researchers aimed to synthesize poly (lactic-co-glycolic acid) (PLGA) microspheres encapsulating hollow CuS nanoparticles (HCuSNPs) and paclitaxel (PTX) that were then labeled with radioiodine-131 (131I) to produce 131I-HCuSNPs-MS-PTX. (more…)

2018年，isoSolutions推出Elysia-raytest放射性药物质量控制仪器
温哥华，不列颠哥伦比亚省(2018) isoSolutions 是集中核医学，放射性同位素研究和核药工业为一体的全球供应商，现宣布在中国推出Elysia-raytest放射性药物质量控制仪器。
isoSolutionsÂ∞ÜÊèê‰æõÂåÖÊã¨Elysia-raytest‰º†Áªü‰ª™Âô®‰∫ßÂìÅÁ≥ªÂàóԺ剪•ÂèäÂÖ®Êñ∞Áöщ∏ĉΩìÂåñË¥®ÈáèÊéßÂà∂ÂÆûÈ™åÂƧԺåÁ∫éÁîü‰∫ßÊîæÂ∞ÑÊÄßËçØÁâ©„ÄÇ (more…)

isoSolutions begins 2018 Representation of Elysia-raytest Quality Control Instruments in CHINA. isoSolutions, a global provider to the nuclear medicine, radioisotope research, and pharmaceutical industries, announces the launch of its representation of the Elysia-raytest radiopharmaceutical Quality Control instrumentation in China.

isoSolutions representation agreement includes Elysia-raytest‚Äôs traditional instrument line, as well as, the all new, all-in-one QC-Cubicle Quality Control laboratory for the production of radiopharmaceuticals. (more…)

Radioimmunotherapy of solid tumors using antibody-targeted¬†radionuclides has been limited by low therapeutic indices (TIs). The article below¬†recently reported a novel 3-step pretargeted radioimmunotherapy¬†(PRIT) strategy based on a glycoprotein A33 (GPA33)‚Äìtargeting¬†bispecific antibody and a small-molecule radioactive hapten (more…)

A recipient of the Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, was selected by Langara College to address scholarship donors on behalf of students at the Donor Recognition event.

Mr. Hazhir Goodarznia was awarded the scholarship last March as a science student who completed a course in marketing. The scholarship highlights the importance of marketing and sales of high-technology, scientifically-intensive products. It honors Brian Armstrong and Will Lepeska, who were pioneers in the new field of nuclear medicine and who, as scientists, focused their efforts on the marketing and sales of medical products. They played a critical role in bringing medical developments from the laboratory to the public and to common usage. (more…)

The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students.

This scholarship is granted to a student at Langara College in Vancouver. ¬†To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in marketing. ¬†This year, two students were funded: ¬†Mr. Hazhir Goodarznia and Mr. Adrian Wong (more…)

isoSolutions, a global provider to the nuclear medicine, Radioisotope research, and Pharmaceutical industries, announces the launch of its representation of the Elysia-Raytest Radiopharmaceutical quality control instrumentation in north and latin america.

The isoSolutions representation agreement includes Elysia-Raytest‚Äôs traditional instrument line, as well as the all new, All-In-One QC-Cubicle Quality Control Laboratory (more…)

isoSolutions, a global provider to the nuclear medicine, radioisotope research, and pharmaceutical industries, today announced the launch of the Elysia-raytest GAIA Ga-68 Synthesizer in North and Latin America. In partnership with Elysia-raytest, isoSolutions supplies a Ga-68 generator compatible with the GAIA Ga-68 Synthesizer.    It is now possible to offer a complete Ga-68 labeling package to all isoSolutions customers in the Americas.

Special pricing conditions are currently available for purchase of the GAIA Ga-68 Synthesizer.

The GAIA Synthesizer, a GMP Peptide Labeling Fluidic Processor, is utilized for the labeling of peptides such as DOTAToc with radioactive metals (e.g. 68Ga). It utilizes single-use synthesis kits optimized for fast and simple production of common tracers. (more…)

isoSolutions, a global provider to the nuclear medicine, radioisotope research, pharmaceutical and medical device industries has formalized an agreement with Europe-based Elysia-raytest as distributor for their line-up of nuclear medicine/PET laboratory instruments in the North American and South American markets. The combined product offerings of the partnership will allow isoSolutions to become a complete solution provider for the nuclear medicine/PET community. (more…)

We regret to announce that Dr. Alexander Susan has passed away peacefully at the age of 83 in Columbia, Missouri. In 2001, Alex Susan and David Drummond, the principal of isoSolutions, formed a joint company ‚Äì Alpha IICH Inc. ‚Äì to develop a supply of alpha emitting radionuclides to researchers for therapeutic applications. Over the years, Alex and David pursued many business opportunities together, merging their international networks of contacts for mutual benefit. Alex became a friend as well as a loyal partner. He will be missed. (more…)

“Applications for molecular imaging technologies continue to increase and our industry continues to expand.‚Äù – David Drummond, Managing Director and Founder of isoSolutions

PET market poised for healthy growth By www.auntminnie.com link
October 11, 2016 — Driven by an increasing prevalence of chronic disorders and greater market penetration of PET systems, the global PET scanner sector will grow at a compound annual growth rate (CAGR) of 4.7% between 2016 and 2026, according to a new report by market research firm Future Market Insights. (more…)

“This is a period of profound change for the Mo-99 supply network that is key to our industry.” РDavid Drummond, Managing Director and Founder of isoSolutions.

By Wayne Forrest, www.auntminnie.com — original link

September 13, 2016 — Supplies of a key radioisotope used in nuclear cardiology scans could be disrupted next month when a Canadian nuclear reactor begins shutting down. U.S. healthcare providers could be left scrambling for new sources of molybdenum-99 (Mo-99) until other suppliers are able to step in and fill the void. (more…)

The role of the Project Coordinator at isoSolutions has been expanded to include responsibility for the Order Desk. Last year, in order to provide improved service to its customers who place routine weekly and monthly orders, isoSolutions established a dedicated order desk.

Responsibility for management and operation of the Order Desk has now been added to the functions of the Project Coordinator. The incumbent, Mr. Gabriel Freitas, is a chemical engineer specialized in project management and controls (MBA) with four years of PMO experience in the pharmaceutical and chemical sector. His background includes experience as a project analyst at a Brazilian based multinational pharmaceutical and cosmetics corporation, Grupo Boticario, and as a process engineer trainee at a multinational specialty chemicals company in France, Croda SAS Chocques. Based on his experience living in foreign countries, he is a fluent Portuguese, English and French speaker. (more…)